A 5-year retrospective study of amisulpride steady-state plasma concentration in patients with schizophrenia in real-life settings based on therapeutic drug monitoring data

Jing Ding; Liu Yang; Xiaohua Cui; Luyao Li; Jiarui Liu; Hongrui Sun; Ting Wang; Yan Zhang

doi:10.1016/j.ajp.2023.103699

A 5-year retrospective study of amisulpride steady-state plasma concentration in patients with schizophrenia in real-life settings based on therapeutic drug monitoring data

Asian J Psychiatr. 2023 Sep:87:103699. doi: 10.1016/j.ajp.2023.103699. Epub 2023 Jul 13.

Authors

Jing Ding¹, Liu Yang¹, Xiaohua Cui¹, Luyao Li¹, Jiarui Liu¹, Hongrui Sun¹, Ting Wang¹, Yan Zhang²

Affiliations

¹ Xi'an Mental Health Center, 710100 Xi'an, PR China.
² Xi'an Mental Health Center, 710100 Xi'an, PR China. Electronic address: zy22661685@163.com.

PMID: 37481912
DOI: 10.1016/j.ajp.2023.103699

Abstract

Objective: Here, we present a retrospective analysis of the last 5 years' data collected in real-life settings as direct evidence to evaluate the optimal therapeutic window of amisulpride (AMI) for psychiatric patients.

Methods: Retrospective analysis of the therapeutic drug monitoring (TDM) results of AMI in outpatients and inpatients were obtained from the Xi'an Mental Health Center from 2017 to 2021.

Results: The interquartile (P₂₅-P₇₅) AMI concentrations ranged 212.20-574.25 ng/mL. The results showed that the proportion of outpatients who received TDM once was significantly higher than that of inpatients who received TDM once (P < 0.001), whereas the reverse was true for those who experienced TDM more than twice (P < 0.001). Higher estimated plasma concentrations were identified in inpatients, female patients, and patients over 59 years of age. Nearly 57.21% of the samples had high concentrations (>320 ng/mL).

Conclusions: The optimal therapeutic reference range for AMI may require reconstruction to guide the use of AMI for the treatment of schizophrenia.

Keywords: Amisulpride; Retrospective analysis; Therapeutic drug monitoring.